Gabelli Announces Partnership with Keeley’s Asset and Wealth Management Services

(Other OTC:GAMI),(OTC US:GAMI),(PinkSheets:TETAA), GREENWICH, Conn. and CHICAGO, May 01, 2025 (GLOBE NEWSWIRE) — GAMCO Investors, Inc. (“Gabelli”) (OTCQX: GAMI) announced today that it has reached an agreement with Teton Advisors, Inc. (OTC Pink: TETAA) for the investment management services business of Keeley – Teton Advisors, LLC (“Keeley”). Keeley consists of four mutual funds and approximately […]

Black Hills Corp. Requests Rate Review and Rider Renewal in Nebraska

(NYSE:BKH), RAPID CITY, S.D., May 01, 2025 (GLOBE NEWSWIRE) — Black Hills Corp. (NYSE: BKH) today announced that its Nebraska natural gas utility has filed a rate review application with the Nebraska Public Service Commission requesting $34.9 million in new annual revenue to recover the necessary capital infrastructure and operational costs required to deliver safe,

Runway Growth Finance Corp. Reschedules Release of First Quarter 2025 Financial Results and Conference Call

(NASDAQ:RWAY), MENLO PARK, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that it has rescheduled its previously announced release of first quarter 2025 financial results to after market

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

(NASDAQ:PHAT), FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior Vice President, Head of Sales, the Company's Board of Directors has approved the

BMO Announces Exercise of its Call Right and Start of Call Measurement Period With Respect to the MicroSectors™ FANG+™ Index 3× Leveraged ETNs (Ticker: FNGA) and Provides a Reminder of the Availability of MicroSectors™ FANG+™ 3× Leveraged ETNs (Ticker: FNGB)

Filed Pursuant to Rule 433Registration Statement No. 333-285508May 1, 2025 Bank of Montreal (“BMO”) (i) announced today that it exercised its call right to redeem all of the outstanding securities of its MicroSectorsTMFANG+TMIndex 3× Leveraged ETNs due January 8, 2038, CUSIP: 063679534 (the “FNGA ETNs”) and that the Call Measurement Period for the FNGA ETNs

Primo Brands Declares Quarterly Dividend

Primo Brands Corporation (NYSE: PRMB) (“Primo Brands” or the “Company”),today announced that its Board of Directors declared a dividend of US$0.10 per share on common shares, payable in cash on June 17, 2025, to shareowners of record at the close of business on June 6, 2025. https://mma.prnewswire.com/media/2678206/Primo_Brands_Corporation__Primo_Brands_Declares_Quarterly_Divide.jpg AboutPrimo Brands Corporation Primo Brands is a leading

Smithfield Foods Declares Quarterly Dividend

Smithfield Foods, Inc. (Nasdaq: SFD), an American food company and an industry leader in value-added packaged meats and fresh pork, today announced its Board of Directors approved a quarterly dividend payment of $0.25 per share of common stock to be paid on May 29, 2025 to shareholders of record at the close of business on

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire May 01, 2025 FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in connection with the appointment of Jonathan Bentley as Senior

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device. DrugSorb-ATR is designed to reduce the severity of bleeding in patients undergoing coronary artery bypass grafting (CABG) surgery within 2 days of stopping

MasTec Reports First Quarter 2025 Results and Raises Financial Guidance for the Year

FirstQuarter 2025 Highlights — Revenue of $2.8 billion increased 6%; strong 21% combined growth contribution from non-pipeline segments; 44% decrease from Pipeline Infrastructure due to large contract close-out last year — 18-month backlog as of March 31, 2025 of $15.9 billion increased 24% year-over-year and 11% versus the prior quarter; significant first quarter additions in

Scroll to Top